Abstract
Purpose
Absence of contrast on contrast enhanced MRI (CEMRI) and reduction in uterine volume at 6 months post-uterine artery embolisation (UAE) currently indicate the successful disruption of the fibroid blood supply by UAE. This study assesses whether 1H MR spectroscopy (1H MRS) can also indicate the success of UAE.
Method
20 patients with symptomatic fibroids were randomised 1:1 to undergo UAE with either Gelfoam or Embospheres. CEMRI and spectra (1.5 T) were acquired pre-, 24-h and 6 months post-UAE. LCModel was used to detect significant levels of choline, creatine and lactate in fibroid spectra. Uterine volumes were measured and paired t tests (p < 0.05) assessed volume reduction over time. Qualitative assessments of CEMRI were performed.
Results
Choline was detected in 17/18 spectra pre-UAE, 12/14 at 24-h and 6/16 at 6 months post-UAE. Choline was not detected in the 7/7 spectra available for the Embospheres group at 6 months. These fibroids were non-enhancing on CEMRI and associated with a significant reduction in mean uterine volume at 6 months (mean/min/max 396.5/84.1/997.5 cm3, p = 0.003). Choline was detected in 6/9 fibroid spectra available for the Gelfoam group at 6 months. Of these fibroids, four demonstrated persistent enhancement on CEMRI and two were non-enhancing. This group did not demonstrate significant uterine volume reduction (mean/min/max 117.2/−230.6/382.6 cm3, p = 0.15). The negative minimum value indicates fibroid growth.
Conclusions
This study has demonstrated the potential of 1H MRS to provide an additional marker of the success of UAE.
Similar content being viewed by others
References
Uterine Artery Embolisation for fibroids. National Institute for Health and Clinical Excellence Web Site. http://publications.nice.org.uk/uterine-artery-embolisation-for-fibroids-ipg367/guidance. Published November 2010. Accessed 14th Oct 2013.
Siddiqui N, Nikolaidis P, Hammond N, Miller FH. Uterine artery embolization: pre- and post- procedural evaluation using magnetic resonance imaging. Abdom Imaging. 2013;38(5):1161–77.
Kirby JM, Burrows D, Haider E, Maizlin Z, Midia M. Utility of MRI before and after Uterine Fibroid Emobolization: why to do it and what to look for. Cardiovasc Intervent Radiol. 2011;34(4):705–16.
Thomason P. Uterine leiomyoma (fibroid) imaging. Medscape website. http://emedicine.medscape.com/article/405676-overview#a2. Published April 4, 2012. Accessed 14th Oct 2013.
Wilde S, Scott-Barrett S. Radiological appearances of uterine fibroids. Indian J Radiol Imaging. 2009;19(3):222–31.
Burn PR, McCall JM, Chinn RJ, Vashisht A, Smith JR, Healy JC. Uterine Fibroleiomyoma: MR imaging appearance before and after embolization of uterine arteries. Radiology. 2000;214(3):729–34.
Harman M, Zeteroğlu Ş, Arslan H, Şengül M, Etlik Ö. Predictive value of magnetic resonance imaging signal and contrast-enhancement characteristics on post-embolization volume reduction of uterine fibroids. Acta Radiol. 2006;47(4):427–35.
Firouznia K, Ghanaati H, Sanaati M, Jalali AH, Shakiba M. Uterine artery embolisation in 101 cases of uterine fibroids: do size, location and number of fibroids affect therapeutic success and complications? Cardiovasc Intervent Radiol. 2008;31(3):521–6.
Spies JB, Roth AR, Jha RC, Levy EB, Chang TC, Ascher SA. Leiomyomata treated with uterine artery embolization: factors associated with successful symptom and imaging outcomes. Radiology. 2002;222(1):45–52.
Smeets AJ, Nijenhuis RJ, van Rooij WJ, Weimar EAM, Boekkooi PF, Lampmann LEH, Vervest HAM, Lohle PNM. Uterine artery embolization in patients with a large fibroid burden: long term clinical and MR follow-up. Cardiovasc Intervent Radiol. 2010;33(5):943–8.
Ananthakrishnan G, Macnaught G, Hinksman L, Gilmour H, Forbes KP, Moss JG. Diffusion-weighted imaging in uterine artery embolisation: do findings correlate with contrast enhancement and volume reduction? Br J Radiol. 1019;2012(85):e1046–50.
Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T. Evaluation of female intrapelvic tumours by clinical proton MR spectroscopy. J Magn Reson Imaging. 2001;13(6):912–7.
Celik O, Sararc K, Hascalik S, Alkan A, Mizrak B, Yologlu S. Magnetic Resonance spectroscopy of uterine leiomyomas. Gynecol Obstet Inves. 2004;58(4):194–201.
Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology. 1993;186(3):745–52.
Julià-Sapé M, Coronel I, Majós C, Candiota AP, Serrallonga M, Cos M, Aguilera C, Acebes JJ, Griffiths JR, Arús C. Prospective diagnostic performance evaluation of single-voxel 1H MRS for typing and grading of brain tumours. NMR Biomed. 2012;25(4):661–73.
Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, Ruijter ET, Ruijs SH. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17(3A):1455–60.
Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, Rodriguez-Vallejo JM. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignany versus benign pathology. Magn Reson Imaging. 1999;17(5):755–65.
Begley JKP, Redpath TW, Bolan PJ, Gilbert FJ. In vivo magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res. 2012;14(2):207–16.
Kwock L, Smith JK, Castillo M, Eqend MG, Collichio F, Morris DE, Bouldin TW, Cush S. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast and prostate cancer. Lancet Oncol. 2006;7(10):859–68.
Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnet Reson Med. 1993;30(6):672–9.
Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599–603.
Chen J-H, Mehta RS, Baek H-M, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su M-Y. Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MR spectroscopy. NMR Biomed. 2011;24(3):316–24.
Horská A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am. 2010;20(3):293–310.
Provencher S. LCModel and LCMgui user manual. http://www.s-provencher.com/pub/LCModel/manual/manual.pdf. Published 14th Sept 2013.
McLean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MY, Earl H, Crawford R, Brenton JD, Griffiths JR, Sala E. Metabolite characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med. 2009;62(4):855–61.
Booth SJ, Pickles MD, Turnbull LW. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG. 2009;116(2):300–3.
Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835–48.
Dorenberg EJ, Novakovic Z, Smith HJ, Hafsahl G, Jakobsen JÅ. Uterine fibroid embolisation can still be improved: observations on post-procedure magnetic resonance imaging. Acta Radiol. 2005;46(5):547–53.
Binkert CA, Andrews RT, Kaufman JA. Utility of nonselective abdominal aortography in demonstrating ovarian artery collaterals in patients undergoing uterine artery embolization for fibroids. J Vasc Interv Radiol. 2001;12(7):841–5.
Pelage J-P, Cazejust J, Pluot E, Le Dref O, Laurent A, Spies JB, Chagnon S, Lacombe P. Uterine fibroid vascularization and clinical relevance to uterine fibroid embolization. Radiographics. 2005;25(suppl 1):S99–117.
McKnight TR, Smith KJ, Chu PW, Chiu KS, Cloyd CP, Chang SM, Phillips JJ, Berger MS. Choline metabolism, proliferation and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J Mag Res Med. 2011;33:808–16.
Wu X, Blanck A, Olovsson M, Moller B, Favini R, Lindblom B. Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. Acta Obstet Gynecol Scand. 2000;79(5):397–404.
Acknowledgments
The authors gratefully acknowledge the funding received from the British Society of Interventional Radiology to carry out this study (Grant Reference 985345).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This study was funded by the British Society of Interventional Radiology (grant number 985345). This is reported in the disclosure forms for authors 1, 4 and 10. All authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Macnaught, G., Ananthakrishnan, G., Hinksman, L. et al. Can 1H MR Spectroscopy be Used to Assess the Success of Uterine Artery Embolisation?. Cardiovasc Intervent Radiol 39, 376–384 (2016). https://doi.org/10.1007/s00270-015-1179-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-015-1179-z